Category Archives: Psoriasis

DetailsCategory: AntibodiesPublished on Thursday, 24 October 2019 09:33Hits: 195

BASEL, Switzerland I October 24, 2019 I Novartis, a leader in rheumatology and immuno-dermatology, announced today that the European Commission (EC) has approved a label update for the up-titration of Cosentyx (secukinumab) to 300 mg for patients with active ankylosing spondylitis (AS).

The approval is based on data from MEASURE 3, a three-year study that explored the tolerability and efficacy of Cosentyx in patients with AS[1]. Response rates were greater in the 300 mg dose group, particularly among patients with previous anti-TNF exposure, compared with the recommended 150 mg dose. The safety profile was consistent with previous studies[1].

This approval gives rheumatologists more flexibility to ensure their patients are able to achieve the best response to treatment, said Sam Khalil, Global Head of Medical Affairs Immunology, Hepatology and Dermatology at Novartis. It further encourages our ongoing efforts to reimagine care to ensure all patients are able to experience full relief from the signs and symptoms of AS.

About axSpAAxial spondyloarthritis (axSpA) is a spectrum of long-term inflammatory disease characterized by chronic inflammatory back pain[16]. The axSpA disease spectrum includes ankylosing spondylitis (AS), in which joint damage is visible on x-ray, and non-radiographic axial spondyloarthritis (nr-axSpA), in which joint damage is not visible on x-ray[16]. Both parts of the disease spectrum have a comparable symptom burden, including nocturnal pain, fatigue, morning stiffness and functional disability[17]. If left untreated, axSpA can impair activity, lead to lost work time, and have a significant impact on quality of life[17].

About Cosentyx (secukinumab)Cosentyx is the first and only fully-human biologic that directly inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation and development of psoriatic arthritis (PsA), psoriasis (PsO), and ankylosing spondylitis (AS)[18],[19].

Cosentyx is backed by robust clinical evidence, including 5-year data across PsO, PsA and AS, as well as data from real world evidence[3]-[15]. These data strengthen the unique position of Cosentyx as a rapid and long-lasting comprehensive treatment across axSpA, PsA, and psoriatic disease, with more than 250,000 patients treated worldwide with Cosentyx since its launcj[20].

About Novartis

Novartis is reimagining medicine to improve and extend peoples lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the worlds top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis or follow @NovartisNews for the latest News & Media Updates at https://twitter.com/novartisnewsFor Novartis multimedia content, please visit http://www.novartis.com/news/media-libraryFor questions about the site or required registration, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

References[1] ClinicalTrials.gov. 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients (MEASURE 3). Available from: https://clinicaltrials.gov/ct2/show/NCT02008916. Last accessed: October 2019.[2] Novartis press release. Novartis Cosentyx positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis. Available from: https://www.novartis.com/news/media-releases/novartis-cosentyx-positive-16-week-prevent-results-advance-potential-new-indication-patients-axial-spondyloarthritis. Last accessed: October 2019.[3] ClinicalTrials.gov. Search of: secukinumab, recruiting, not yet recruiting, active, not recruiting, completed, enrolling by invitation studies. Listed results on ClinicalTrials.gov [online]. Available from: https://clinicaltrials.gov/ct2/results?term=secukinumab&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&recrs=e&age_v=&gndr=&type=&rslt= [Last accessed: October 2019].[4] ClinicalTrials.gov. Comparison of Secukinumab versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab (ARROW). NCT03553823. Available from: https://clinicaltrials.gov/ct2/show/NCT03553823 [Last accessed: October 2019].[5] Langley RG, et al. Secukinumab in plaque psoriasisresults of two phase 3 trials. N Engl J Med 2014;371:326338.[6] Bagel J, et al. Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results). Dermatol Ther 2018;8:571579.[7] ClinicalTrials.gov. Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as compared to GP2017 (Adalimumab Biosimilar) (SURPASS). NCT03259074. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03259074 [Last accessed: October 2019].[8] Blauvelt A, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol 2017;76:6069.[9] Bissonnette R et al. Secukinumab demonstrates high sustained efficacy and a favorable safety profile through 5 years of treatment in moderate to severe psoriasis. Presented as eposter P2223 at 26th EADV Congress 2017. 13th October 2017.[10] Mease PJ, et al. Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial. Abstract presented at the American College of Rheumatology Annual Meeting, 2018.[11] MEASURE 2. Novartis data on file.[12] Holdsworth E et al. Real world physician satisfaction with secukinumab in Psoriatic Arthritis and Ankylosing Spondylitis in Europe. Presented at EULAR 2019.[13] Michelsen B et al. Remission and drug retention rates of secukinumab in 1549 patients with psoriatic arthritis treated in routine care pooled data from the observational EuroSpA Research Collaboration Network. Presented at EULAR 2019.[14] Michelsen B et al. Pooled 6-month treatment outcomes and drug retention rates in 1556 patients with axial spondyloarthritis treated with secukinumab in routine clinical practice in 12 European Countries in the EuroSpA Research Collaboration. Presented at EULAR 2019.[15] Baraliakos X et al. Long-term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial. Presented as a late-breaking abstract at the American College of Rheumatology Annual Meeting, 2018.[16] Strand V, et al. Patient Burden of Axial Spondyloarthritis. J Clin Rheumatol. 2017 Oct; 23(7): 383391.[17] Mease PJ, van der Heijde D, Karki C, et al. Characterization of patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis in the US-based Corrona Registry. Arthritis Care Res (Hoboken). 2018;70(11):1661-1670.[18] Novartis Europharm Limited. Cosentyx (secukinumab): Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf. Last accessed: October 2019.[19] Girolomoni G, et al. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 2012; 167:717724.[20] Novartis data on file. September 2019.

SOURCE: Novartis

Go here to see the original:
Novartis receives approval for Cosentyx label update in Europe to include dosing flexibility in ankylosing spondylitis | Antibodies | News Channels -...

DUBLIN--(BUSINESS WIRE)--The "Psoriasis Drugs - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

The Psoriasis Drugs market worldwide is projected to grow by US$10.8 Billion, driven by a compounded growth of 9%

Tumor Necrosis Factor Inhibitor, one of the segments analyzed and sized in this study, displays the potential to grow at over 9%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$8.1 Billion by the year 2025, Tumor Necrosis Factor Inhibitor will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 7.6% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$367.7 Million to the region's size and clout in the next 5 to 6 years. Over US$321.2 Million worth of projected demand in the region will come from the rest of the European markets. In Japan, Tumor Necrosis Factor Inhibitor will reach a market size of US$377.2 Million by the close of the analysis period.

As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 13.2% over the next couple of years and add approximately US$3.1 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.

Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio.

Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include:

Key Topics Covered:

1. Market Overview

2. Focus On Select Players

3. Market Trends & Drivers

4. Global Market Perspective

For more information about this report visit https://www.researchandmarkets.com/r/8dk80z

View post:
Psoriasis Drugs Market Analysis, Trends, and Forecasts, 2025 - Global Market is Projected to Grow by $10.8 Billion - ResearchAndMarkets.com - Business...

Published on October 24, 2019

Contributed by Dr. Sravya Chowdary Tipirneni, Consultant Dermatologist, Columbia Asia Hospital Whitefield

Nutrition affects every aspect of health. Psoriasis, an autoimmune condition that features dry, itchy, and scaly skin, may be one condition to which diet can make a difference.

When you have psoriasis, reducing triggers is an important part of managing your condition and avoiding flare-ups. Psoriasis flare-ups can be caused by a variety of triggers. These triggers may include bad weather, excess stress, and also watching whats on your plate!

A healthy diet lots of fruits and veggies, lean protein, and whole grains is a good idea for just about everyone. But some people who have psoriasis say their eating habits can affect their skin.

Limit Alcohol

The link between alcohol and psoriasis isnt clear, butif you drink, be moderate. For men, that means no more than two drinks a day, and for women no more than one.

Studies show that men who drink heavily dont respond to psoriasis treatments as well. And some research suggests that people who have psoriasis and drink heavily may find that their skin gets better when they stop.

If your condition is especially severe or you take certain medications, like methotrexate and acitretin, your dermatologist may tell you to stay away from alcoholcompletely.

Food that fight inflammation

Some studies suggest that antioxidants, like vitamin C, vitamin E, beta-carotene, and selenium, may make a difference. And some research suggests fatty acids from fish oil can be helpful.

Anti-inflammatory foods are generally healthy, so it shouldnt hurt to give them a try.

They include:

Fatty fish

A diet high in fatty fish can provide the body with anti-inflammatory omega-3s. The intake of omega-3s has been linked to a decrease of inflammatory substances and overall inflammation.

Fish to eat include:

Heart-healthy oils

Like fatty fish, certain vegetable oils also contain anti-inflammatory fatty acids. Its important to focus on oils that have a higher ratio of omega-3 to omega-6 fatty acids.

Oils to eat include:

Processed foods

Eating too many processed, high-calorie foods can lead to obesity, metabolic syndrome, and a variety of chronic health conditions. Certain conditions such as these cause chronic inflammation in the body, which may be linked to psoriasis flare-ups.

Foods to avoid include:

Nightshades

One of the most commonly reported triggers for psoriasis flare-ups is the consumption of nightshades. Nightshade plants contain solanine, which has been known to affect digestion in humans and may be a cause of inflammation.

Foods to avoid include:

Nutritional supplements

Fish oil, vitamin D, vitamin B-12, and selenium have all been researched for psoriasis.

Benefits of supplementation with these nutrients may include a decrease in the frequency and severity of flare-ups.

Lose Weight

People who are overweight or obese have a greater chance of getting psoriasis, and their symptoms tend to be worse. Studies suggest that your skin may get better if you shed extra pounds. This may be because fat cells make certain proteins that can trigger inflammation and make the condition worse.

Gluten-Free Diet

You may wonder whether your psoriasis would get better if you ate a gluten-free diet. Although you may hear about success stories from others who have tried it, so far studies arent clear that it helps. More research is needed.

Foods to avoid include:

The vegan diet:

This may also benefit people with psoriasis. This diet is naturally low in inflammatory foods such as red meat and dairy. Its high in anti-inflammatory foods such as fruits, vegetables, and healthy oils.

The Mediterranean diet:

This diet is well known for its numerous health benefits, including a reduced risk of certain chronic diseases. This diet focuses on foods that are high in antioxidants and healthy fats. It limits foods that are often considered to be pro-inflammatory.

The Paleo diet:

This diet places an emphasis on eating whole foods and avoiding processed foods. Since many whole foods contain anti-inflammatory compounds, this diet may prove to be beneficial for people with psoriasis.

Psoriasis is a life-long condition, and its severity can fluctuate. Medical treatment often aims to reduce skin cell production in order to minimize flares, or the periodic worsening of symptoms. Some lifestyle changes may also help.

In combination with medicine, nutrition may be a potent player in the fight against psoriasis.

Read more here:
Foods to eat and avoid if you are suffering from Psoriasis - APN News

Text size

The drugmaker Eli Lilly has struggled this year, with the stock down 6.7% in 2019. That is well behind the broader S&P 500 health-care sector, which is up 6%, and the broader S&P 500, which is up 19.9% since the start of the year.

The company will make its case on Wednesday morning when it unveils its third-quarter earnings. Lilly has scheduled a conference call for 9 a.m. ET.

The earnings report comes weeks after a double-dose of good news for Eli Lilly (ticker: LLY). Earlier this month, the Food and Drug Administration approved the companys migraine drug Reyvow, and the company unveiled positive data on its drug Taltz in pediatric patients with plaque psoriasis, all in the space of two days.

Eli Lilly stock trades at 16.9 times its estimated earnings over the next 12 months, slightly below its five-year average of 19.8 times earnings.

Heres a snapshot of investors expectations and recent history.

Wall Street analysts expect earnings of $1.39 per share in the third quarter, according to FactSet, and sales of $5.5 billion.

In a note out October 18, J.P. Morgan analyst Chris Schott wrote that he expected growth on the sale of core products. Strong product trends continue despite competition, Schott wrote.

The companys anti-inflammatory drug Taltz is facing an increasingly crowded field, including AbbVies (ABBV) new drug Skyrizi and other drugs from Novartis (NVS), Celgene (CELG). Still, Schott wrote that Taltz has shown relatively healthy performance despite the Skyrizi launch.

On October 16, Bank of America Merrill Lynch analyst Geoff Meacham issued a Buy rating on Lilly, writing that he viewed the risk/reward profile in Lilly as compelling, and setting a $133 price target on the stock.

The company has reported some promising data in recent months, including a strong response rate for its drug LOXO-292 in some lung cancer patients, and the data on Taltz in pediatric patients with plaque psoriasis.

In July, Lilly reported earnings per share of $1.50, beating Wall Street expectations of $1.45 just slightly. The company attributed the beat to an increase in volume.

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com

Visit link:
Eli Lilly Reports Earnings Tomorrow. Heres What to Expect. - Barron's

havinPsoriasis is associated with jokeIf there is an increased risk of cancer, a new overview of the studies is available.

Researchers writing in JAMA Dermatology combined data from 58 studies and found that psoriasis levels of all severity increased by 18 percent, and 22 percent were associated with severe psoriasis, compared to those without disease. Cancer mortality was increased in all cases of severe psoriasis.

For some specific cancers, the risk was even higher. For example, they found that severe psoriasis was associated with a more than eleven-fold risk of squamous cell carcinoma (skin cancer), such as twice the risk of oesophageal and liver cancer and a 45 percent increased risk of pancreatic cancer.

Any degree of psoriasis, whether severe or not, was significantly associated with, inter alia, colon cancer, non-Hodgkin's lymphoma and cancers of the kidney and pancreas.

The reason for the association is unclear, but there is a known link between chronic inflammation and cancer and this may help explain the relationship.

Read the original:
Psoriasis associated with increased cancer risk - asume tech

INDIANAPOLIS, Oct. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis, demonstrating that 89 percent of patients treated with Taltz achieved a significant 75 percent improvement from baseline to Week 12 on their Psoriasis Area and Severity Index score (PASI 75) and 81 percent of patients treated with Taltz achieved a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1). Results of the study are being presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain. Based on these positive results, Lilly plans to submit for U.S. regulatory approval for pediatric patients with moderate to severe plaque psoriasis.

"Results from our study indicate that Taltz may have the potential to clear skin and reduce itch in pediatric patients with moderate to severe plaque psoriasis," said study investigator Kim Papp, MD, PhD, Probity Medical Research, Inc., Waterloo, Ontario, Canada. "While it is estimated that up to one third of people with psoriasis first develop symptoms during childhood, there are limited medications available for pediatric patients. This study provides encouraging data supporting the potential for Taltz to become another treatment option for this patient population."

The co-primary endpoints of the study were the proportion of patients achieving a significant 75 percent improvement from baseline on their Psoriasis Area and Severity Index score (PASI 75) and a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1) at Week 12. Key secondary endpoints included the proportion of patients achieving PASI 90, sPGA (0) and PASI 100 at Week 12, and at least a four-point improvement in Itch Numeric Rating Scale (Itch NRS 4) among patients with baseline Itch NRS 4 at Week 12, as well as PASI 75 and sPGA 0,1 at Week 4. The proportion of patients achieving 0 or 1 on the Children's Dermatology Life Quality Index (CDLQI, patients 6 to 16 years old) or DLQI (patients 17 years old) at Week 12 was also evaluated.

"We recognize that psoriasis can have a significant impact on children and adolescents, causing challenging symptoms and affecting their self-esteem and ability to connect to peers," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. "We're pleased to see positive results for Taltz in pediatric patients. These results build on more than five years of safety and efficacy data in adults and support the potential for Taltz in this new population, pending regulatory approvals."

A total of 201 patients aged 6 to <18 years of age with moderate to severe plaque psoriasis were randomized to receive Taltz (20 mg for <25 kg, 40 mg for 25-50 kg or 80 mg for >50 kg through Week 12, with 40 mg, 80 mg or 160 mg starting doses, respectively) or placebo. At 12 weeks, the proportion of patients achieving the co-primary endpoints was superior to placebo with statistically significant difference (P<0.001), including:

Taltz also met all major secondary endpoints in the study (P<0.001).

In this trial, the overall safety profile of Taltz was consistent with previously reported results. The Taltz safety profile has been studied across 15 clinical trials in plaque psoriasis and psoriatic arthritis, with 6,989 patients receiving Taltz, with a total exposure of 16,586 patient-years.1,2,3

INDICATIONS AND USAGE FOR TALTZTaltz is approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Taltz is also approved for the treatment of adults with active psoriatic arthritis and active ankylosing spondylitis.

IMPORTANT SAFETY INFORMATION FOR TALTZ

CONTRAINDICATIONSTaltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONSInfectionsTaltz may increase the risk of infection. In clinical trials of patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of patients with psoriatic arthritis and ankylosing spondylitis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for TuberculosisEvaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

HypersensitivitySerious hypersensitivity reactions, including angioedema and urticaria (each 0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel DiseaseDuring Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease. Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz 80 mg Q2W group (Crohn's disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials in patients with plaque psoriasis and in the Taltz Q4W group in ankylosing spondylitis trials (Crohn's disease 1.0% [2 patients], ulcerative colitis 0.5% [1 patient]) than in the placebo group (Crohn's disease 0.5% [1 patient], ulcerative colitis 0%). In the ankylosing spondylitis trials, serious events occurred in 1 patient in the Taltz group and 1 patient in the placebo group.

ImmunizationsPrior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONSMost common adverse reactions (1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in patients with psoriatic arthritis and ankylosing spondylitis were consistent with the safety profile in patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis.

Please see accompanying Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.

IX HCP ISI 23AUG2019

About TaltzTaltz (ixekizumab) is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.4 IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Taltz inhibits the release of pro-inflammatory cytokines and chemokines.4

About Moderate to Severe Plaque Psoriasis Psoriasis is a chronic, immune disease that affects the skin.5 It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis affects approximately 125 million people worldwide, approximately 20 percent of whom have moderate to severe plaque psoriasis.5,6 The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.5 Patients with plaque psoriasis often have other serious health conditions, such as diabetes and heart disease and experience negative impact on their quality of life.5

About the Phase 3 Pediatric Study This study is a Phase 3, multicenter, randomized, double-blinded, placebo controlled study to evaluate safety, tolerability and efficacy of Taltz in patients from 6 to <18 years of age with moderate to severe plaque psoriasis. The co-primary endpoints of the study were the proportion of patients achieving a 75 percent improvement from baseline on their Psoriasis Area and Severity Index score (PASI 75) and a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1) at Week 12. Key secondary endpoints included the proportion of patients achieving PASI 90, sPGA 0 and PASI 100 at Week 12, and at least a four-point improvement in Itch numeric rating scale (Itch NRS 4) among patients with baseline Itch NRS 4 at Week 12, as well as PASI 75 and sPGA 0,1 at Week 4. The proportion of patients achieving 0 or 1 on the Children's Dermatology Life Quality Index (CDLQI, patients 6 to 16 years old) or DLQI (patients 17 years old) at Week 12 was also evaluated.

About Lilly in DermatologyBy following the science through unchartered territory, we continue Lilly's legacy of delivering innovative medicines that address unmet needs and have significant impacts on people's lives around the world. Skin-related diseases are more than skin deep. We understand the devastating impact this can have on people's lives. At Lilly, we are relentlessly pursuing a robust dermatology pipeline to provide innovative, patient-centered solutions so patients with skin-related diseases can aspire to live life without limitations.

About Eli Lilly and CompanyLilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom. P-LLY

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab) as a potential treatment for pediatric patients with moderate to severe plaque psoriasis, and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date, that Taltz will receive additional regulatory approvals, or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertake no duty to update forward-looking statements to reflect events after the date of this release.

1 Data on file. Lilly USA, LLC. TAL20171211A.2 Data on file. Lilly USA, LLC. DOF-IX-US-0019.3 Mease P, Roussou E, Burmester GR, et al. Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials. Arth Care Res. 2018 (Epub). doi:10.1002/acr.23738.4 Taltz Prescribing Information, 2019.5 Psoriasis media kit. National Psoriasis Foundation website. https://www.psoriasis.org/sites/default/files/for-media/MediaKit.pdf. Accessed September, 2019.6 Skin conditions by the numbers. American Academy of Dermatology website. https://www.aad.org/media/stats/conditions/skin-conditions-by-the-numbers. Accessed September, 2019.

SOURCE Eli Lilly and Company

https://www.lilly.com/

Read the original post:
Lilly Presents Positive Results for Taltz (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European...

MUMBAI, India and PRINCETON, N.J., Oct. 9, 2019 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries presented long-term follow-up data from ILUMYA (tildrakizumab-asmn) Phase 3 reSURFACE 1 and 2 trials at the 28th European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain.

The data showed that the significant response rates seen in the initial 52 and 64 weeks, respectively, were maintained over four years for people with moderate-to-severe plaque psoriasis, with more than half of participants achieving at least 90 percent skin clearance (Psoriasis Area Sensitivity Index (PASI) 90) and no new safety concerns recorded.1,2 Additional study analyses showed that the 75 to 100 percent skin clearance achieved with ILUMYA treatment over three years was sustained equally in people with and without metabolic syndrome,3,4 a common condition in people with psoriasis.5

Click to Tweet #NEWS: @SunPharma_Live presents long-term data showing significant skin clearance response maintained in people with moderate-to-severe plaque psoriasis over four years at #EADV2019. Read more: https://bit.ly/2F4CEoo

"Psoriasis is an individualized condition and it can be a challenge for clinicians to prescribe a medicine that's effective over time, especially for patients with co-morbid conditions like metabolic syndrome," said Jeffrey Crowley, M.D., Bakersfield Dermatology, Bakersfield, California. "These data provide confidence that ILUMYA can help patients with moderate-to-severe plaque psoriasis, regardless of metabolic syndrome, achieve and maintain significant skin clearance over the long-term."

Eligible participants in the ILUMYA Phase 3 reSURFACE 1 and 2 trials who remained on treatment for the open-label extension studies received ILUMYA for a total of 208 weeks (reSURFACE 1) and 200 weeks (reSURFACE 2).1,2 After four years, ILUMYA treatment led to significant and durable observed improvements in PASI and Physician Global Assessment (PGA) scores key measures of disease severity.1,2

ILUMYA 100 mg was well-tolerated, with a low rate of adverse events (AEs) that were comparable or numerically lower than placebo based upon exposure-adjusted rates for many AE categories.1,2

Researchers also analyzed the reSURFACE 1 and reSURFACE 2 studies to glean insights into whether ILUMYA's efficacy was similar in people with metabolic syndrome (defined as elevated blood pressure, body mass index/obesity, triglycerides and glucose and low HDL cholesterol levels), as this co-morbid condition can negatively affect people's response to most biologic psoriasis medicines.6 This post-hoc analysis showed that the skin clearance levels achieved and sustained with ILUMYA 100 mg at three years were comparable in participants with and without metabolic syndrome.3,4

Three-year adverse event rates usually associated with metabolic syndrome, such as infections, cardiovascular events or complications of diabetes, were no different in study participants with and without metabolic syndrome.3,4

"Moderate-to-severe psoriasis is a lifelong condition, and at Sun Pharma we're committed to helping people find treatment options that work consistently over time, regardless of any co-morbid conditions, to help manage the frustrating symptoms that for so many years are a part of everyday life," said Alan Mendelsohn, M.D., Associate Vice President, Dermatology Medical Affairs, Sun Pharma. "ILUMYA has been proven to provide significant skin clearance that begins soon after initial use and is maintained for years, with just four doses a year following two starter doses, without demonstrating any new or increased risk of safety events."

About the Studies

reSURFACE 1 Extension StudyreSURFACE 1 was a three-part, double-blind, randomized, controlled, 64-week study that evaluated ILUMYA 100 mg and 200 mg at weeks 0 and 4, and every subsequent 12 weeks in adults with moderate-to-severe chronic plaque psoriasis. Participants with at least 50 percent improvement in PASI 50 at base study completion who received ILUMYA within 12 weeks of base study end (week 64) were eligible to enroll in the extension study and continued on the same ILUMYA dose once every 12 weeks. Researchers evaluated PASI and PGA response (score of 0 or 1 with 2 grade reduction from baseline) and incidence rates for prespecified adverse events, including severe infections, cardiovascular events and drug-related hypersensitivities.

reSURFACE 2 Extension StudyreSURFACE 2 was a three-part, double-blind, randomized, controlled, 52-week study that compared the safety and efficacy of ILUMYA 100 mg and 200 mg to placebo and etanercept 50 mg. At Week 12, patients with at least a 50 percent improvement in PASI 50 at base study completion on ILUMYA 100 or 200 mg were eligible to enroll in the extension study and continued on the same ILUMYA dose every 12 weeks. Partial and non-responders to etanercept were converted to treatment with ILUMYA200 mg, while responders (PASI 75) were discontinued. Researchers evaluated PASI and PGA response (score of 0 or 1 with 2 grade reduction from baseline) and incidence rates for prespecified adverse events, including severe infections, cardiovascular events and drug-related hypersensitivities.

reSURFACE 1 and reSURFACE 2 Post-Hoc AnalysesPost-hoc analyses of reSURFACE 1 and reSURFACE 2 were conducted to evaluate changes in ILUMYA's efficacy in people with and without metabolic syndrome, which was previously defined as those who met the National Cholesterol Education Program-Adult Treatment Panel III criteria (including elevated blood pressure, body mass index [BMI], triglycerides, and glucose). Researchers stratified efficacy results determined by proportion of patients with at least PASI 75 and absolute and median percent PASI change from baseline up to week 148 in both studies.

About ILUMYA(tildrakizumab-asmn)

ILUMYA (tildrakizumab-asmn) is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, in the United States. ILUMYA has also been approved for moderate-to-severe plaque psoriasis in Australia and under the brand name ILUMETRITM in Europe.

INDICATION AND IMPORTANT SAFETY INFORMATION

ILUMYA (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

CONTRAINDICATIONS

ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS:

Hypersensitivity: Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy.

Infections: ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves.

Pretreatment Evaluation for Tuberculosis: Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after treatment.

Immunizations: Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines.

Adverse Reactions: The most common (1%) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.

Please click here for Full Prescribing Information and Medication Guide.

About Sun Dermatology

Sun Dermatology (the branded dermatology division of a wholly owned subsidiary of Sun Pharmaceutical Industries Inc.) is committed to expanding its dermatology portfolio to bring healthcare providers and patients around the world more treatment options and ongoing support for conditions like moderate-to-severe plaque psoriasis. Sun Pharmaceutical Industries Ltd., along with its subsidiaries, is ranked second in dermatology prescription volume within the U.S. per IQVIA and is the fourth largest specialty generic pharmaceutical company globally. In addition to ILUMYA, Sun Dermatology is comprised of several branded products with a focus on various dermatologic conditions.

About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 7% of annual revenues in R&D. For further information, please visit http://www.sunpharma.com & follow us on Twitter @SunPharma_Live.

Disclaimer

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied.

References

Contacts:

SOURCE Sun Pharmaceutical Industries Ltd.

http://www.sunpharma.com

Read the rest here:
Sun Pharma Presents Long-term Study Results that Show Significant Skin Clearance with ILUMYA (tildrakizumab-asmn) Maintained Over Four Years in People...

Persons with ankylosing spondylitis (AS)with or without psoriasishave different demographic, genetic, radiographic, and clinical variables from persons with axial psoriatic arthritis (axPsA), according to results of a new study. The findings suggest that axPsA is a distinct entity.

The researchers compared data of patients with AS with psoriasis (n=91) and patients with AS without psoriasis (n=675) with data of patients with axPsA (n=477) and patients with peripheral PsA (n=826).

DMARDs May Improve Bone Structure in PsA

Intravenous Biologic May Inhibit Radiographic Progression in PsA

All patients cases were followed prospectively using the same protocol. A logistic regression analysis was performed and adjusted for follow-up duration.

Results showed that patients with AS with or without psoriasis were younger, were more often male, were positive for HLA-B*27 antigen, had received more treatment with biologics, and had a higher grade of sacroiliitis.

Additionally, patients with AS had more back pain at presentation, worse Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Metrology Index scores, and worse physician global assessments.

Similar differences were detected when patients with AS and psoriasis were compared with those with axPsA, and in a regression model.

Melinda Stevens

Reference:

Feld J, Ye JY, Chandran V, et al. Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis? [published online October 8, 2019]. Rheumatology. doi:10.1093/rheumatology/kez457.

View post:
Researchers Identify Differences Between Axial Psoriatic Arthritis and Ankylosing Spondylitis - Consultant360

A SCOTS psoriasis sufferer has told how the condition has impacted her relationship by leaving her not wanting to be "touched, cuddled or kissed".

Jude Duncan, 26, has had the irritating skin condition for six years and says it can affect intimate relationships and dating.

4

The marketing officer, who is a 'Skinfluencer' on Instagram has been with her boyfriend for two years and says she is lucky that he is very supportive.

But she also has moments where her itchy and flaky skin affects her mental health and leaves her not wanting intimacy.

Psoriasis, which affects around 2 per cent of people in the UK, is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.

Jude, from Gourock, told the Scottish Sun: "Im very lucky to have a supportive partner but I know that if I'm not having a great nights sleep, and tossing and turning, then hes not getting a great nights sleep and that can have an impact on them as well.

"Actually having that communication with a partner is really important but it can be really difficult as well for people to open up.

"I'm in a lucky position where I feel very confident with my psoriasis but also sometimes it has felt like if I'm having a flare up I dont want to be touched, I dont want to cuddled, I dont want to be kissed. So it does have that impact on it.

4

"I wouldn't say that because Im with someone I havent had those difficulties."

She added: "Its very hard to get your partner to understand what you're going through mentally as well as the physical aspect of it.

"And the fact that they cant do anything to help puts a strain on it, so its just different."

Jude also had a period of time before she was in a relationship where she was trying to date - but potential suitors were put off by her condition.

She has hit out at the 'Insta perfect' world which means people can be very shallow and focus on a person's perceived flaws.

She said: "On every date I would be asked 'what's wrong with your face' and stuff like that, so it was definitely a topic of conversation.

4

4

"It was the elephant in the room, like when is this going to be brought up.' And thats not how it should be.

"It shouldnt matter if I have a bit of psoriasis on my face or not whether you want a second date, but it really did impact that a lot.

"We live in this Insta perfect world where people with flaws or differences arent seen to be good enough and people dont want to be seen with someone like that.

"But to be honest with you if you have a problem with how I look, I dont really want to date anyone that treats people like that anyway."

Negative affect on Mental Health

Speaking on Mental Health day, Jude explained how various factors surrounding the condition can affect a person's mental wellness.

That includes the discomfort itself, but also the negative impact of how other people treat you.

Stats show that 67 per cent of sufferers believe that the condition can have an affect on your mental health.

Jude said: "If you are uncomfortable and thats causing you to not sleep then thats going to have an affect on your mental health, but also just that uncomfortableness all the time, being in a constant state of irritation, not being able to relax - that is going to have a toll on your mental health.

"A lot of people are like oh lets focus on treating the skin but they dont look at surrounding factors such as mental health.

"Because its such a visual condition it can make you incredibly insecure and really lonely and isolated because it's not really talked about. So that can also have an impact on your mental health because you feel like youre bottling it up and not talking about it.

"If youre not getting any sleep that means the next day you're not going to be functioning to your full potential, and you're stressing yourself out because you're not maybe getting as much done as you want and that's going to result in you stressing out more, which is going to affect your sleep, which is going to affect your mental health and its just a really vicious cycle.

Mental health stats:

Sleep stat:

Relationships stat:

Public perception stat:

Call to action

BODY FIND Man's body discovered in Glasgow flat

Latest

CRASH DRAMA Person cut from vehicle in Invergordon crash between car and lorry as A9 closed

'JACK IS NOW SAFE' Dog used in 'drugged' state by beggars in Edinburgh rescued

HOME ATTACK Man, 37, suffers 'significant injuries' in Greenock as cops probe murder bid

'Cannae go wrong' Haggis, cheese and chips roll divides Scots punters online

Exclusive

grounded force Sozzled cop banned from holiday after allegedly abusing staff at airport

"I think for me as well, when people stare or make comments, sometimes they mean well but that can really also play on your mental health."

She added: "I definitely had comments in the past. I've had people say really horrible things to my face.

"But I'm OK that in that I'm in a position where I'm confident enough. There's so many people out there that arent and a situation like that would knock their confidence.

"I was in a position that I was able to move on and deal with it but thats not always the case."

If you are affected by any of the issues raised in this article, please call the Samaritans on (free) 116123.

We pay for your stories and videos! Do you have a story or video for The Scottish Sun? Email us at scoop@thesun.co.uk or call 0141 420 5300

Read the original here:
Scots psoriasis sufferer opens up on how skin condition can affect mental health and leave her not wanting to - The Scottish Sun

NORTH CHICAGO, Ill., Oct. 9, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new results evaluating the safety and efficacy of SKYRIZI (risankizumab) at 2.5 years in adult patients with moderate to severe plaque psoriasis, as well as additional data on HUMIRA (adalimumab) and the investigational JAK inhibitor upadacitinib, at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, in Madrid.

"Leveraging more than two decades of clinical experience with HUMIRA, AbbVie recently expanded its dermatology portfolio with the approval of SKYRIZI for patients living with moderate to severe plaque psoriasis," said Marek Honczarenko, MD, PhD, vice president, global immunology development, AbbVie. "The new data presented at EADV will advance the knowledge around new and existing treatments for serious skin diseases, like psoriasis, as well as diseases with high levels of unmet need, such as atopic dermatitis and hidradenitis suppurativa."

In addition to sharing new long-term data from the LIMMitless open-label extension study in moderate to severe plaque psoriasis, AbbVie will share results from its ongoing investigational Phase 2 program evaluating risankizumab for the treatment of psoriatic arthritis. Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

In addition, Phase 2b results evaluating time to treatment response with upadacitinib, an oral JAK inhibitor, under investigation for patients with moderate to severe atopic dermatitis will be shared as an oral presentation. Upadacitinib is not approved for atopic dermatitis by any regulatory authority, and its safety and efficacy have not been established in this indication.

Additional presentations include efficacy and safety results further evaluating HUMIRA in hidradenitis suppurativa.

"Chronic skin diseases can have a significant physical and psychosocial impact on patients," said Jean-Marie Meurant, board president of the International Alliance of Dermatology Patient Organizations. "While progress has been made to improve the lives of patients, many still do not have access to the treatment and care they need and deserve. It's critical that the scientific community build upon current research to better understand these diseases and continue to keep the patient experience at the forefront of their efforts."

AbbVie Data at EADV

Risankizumab Abstracts Psoriasis

Psoriatic arthritis

Upadacitinib AbstractsAtopic dermatitis

HUMIRA AbstractsPsoriasis

Hidradenitis suppurativa

Disease State AbstractsHidradenitis suppurativa

About SKYRIZI (risankizumab) in the EU1

SKYRIZI (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Important EU Safety Information1

SKYRIZI is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients and in clinically important active infections. SKYRIZI may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, SKYRIZI should be used with caution. Treatment with SKYRIZI should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

Prior to initiating treatment with SKYRIZI, patients should be evaluated for tuberculosis (TB) infection. Patients receiving SKYRIZI should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating SKYRIZI in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

The most frequently reported adverse reactions were upper respiratory infections, which occurred in 13 percent of patients. Commonly (greater than or equal to 1/100 to less than 1/10) reported adverse reactions included tinea infections, headache, pruritus, fatigue and injection site reactions.

This is not a complete summary of all safety information. See the full summary of product characteristics (SmPC) at http://www.ema.europa.eu. Globally, prescribing information varies; refer to the individual country product label for complete information.

About Upadacitinib

Discovered and developed by AbbVie, upadacitinib is an investigational, oral, small molecule JAK inhibitor being studied for moderately to severely active rheumatoid arthritis and other immune-mediated inflammatory diseases.2-15 Phase 3 trials of upadacitinib in psoriatic arthritis, Crohn's disease, atopic dermatitis and ulcerative colitis are ongoing and it is also being investigated to treat ankylosing spondylitis and giant cell arteritis.10-15

About HUMIRA in the EU16

HUMIRA is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.

HUMIRA is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy.

Important EU Safety Information16

HUMIRA is contraindicated in patients with active tuberculosis or other severe infections such as sepsis, and opportunistic infections and in patients with moderate to severe heart failure (NYHA class III/IV). It is also contraindicated in patients hypersensitive to the active substance or to any of the excipients; serious allergic reactions including anaphylaxis have been reported. The use of HUMIRA increases the risk of developing serious infections, including hepatitis B reactivation, which may, in rare cases, be life-threatening. Rare cases of lymphoma and leukemia have been reported in patients treated with HUMIRA. On rare occasions, a severe type of cancer called hepatosplenic T-cell lymphoma has been observed and often results in death. A risk for the development of malignancies in patients treated with TNF-antagonists cannot be excluded. Rare cases of pancytopenia, aplastic anaemia, demyelinating disease, lupus, lupus-related conditions and Stevens-Johnson syndrome have been reported in patients treated with HUMIRA. The most frequently reported adverse events across all indications included respiratory infections, injection site reactions, headache and musculoskeletal pain.

This is not a complete summary of all safety information. Globally, prescribing information varies; refer to the individual country product label for complete information.

Full summary of product characteristics is available at: http://www.ema.europa.eu

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at http://www.abbvie.com. Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2018 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References:

View original content:http://www.prnewswire.com/news-releases/abbvie-announces-new-data-from-its-dermatology-portfolio-and-pipeline-at-the-28th-european-academy-of-dermatology-and-venereology-eadv-congress-300934529.html

SOURCE AbbVie

Company Codes: NYSE:ABBV

See original here:
AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress -...